QT
AKRO

Quantbot Technologies’s Akero Therapeutics AKRO Stock Holding History

Quantbot Technologies’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,335
Closed -$206K – 1673
2025
Q3 		$206K Buy
+4,335
New +$210K 0.01% 1286
2024
Q2 		– Sell
-1,100
Closed -$27.8K – 1394
2024
Q1 		$27.8K Buy
+1,100
New +$26.4K ﹤0.01% 1389
2023
Q1 		– Sell
-18,818
Closed -$1.03M – 1503
2022
Q4 		$1.03M Buy
+18,818
New +$806K 0.07% 372
2022
Q3 		– Sell
-10,100
Closed -$95K – 1549
2022
Q2 		$95K Buy
10,100
+8,691
+617% +$90.6K 0.01% 1158
2022
Q1 		$19K Sell
1,409
-1,464
-51% -$25.6K ﹤0.01% 1366
2021
Q4 		$60K Sell
2,873
-1,100
-28% -$24.4K ﹤0.01% 983
2021
Q3 		$88K Buy
3,973
+3,373
+562% +$76.4K 0.01% 992
2021
Q2 		$14K Buy
600
+400
+200% +$11.2K ﹤0.01% 1264
2021
Q1 		$5K Hold
200
– – ﹤0.01% 1296
2020
Q4 		$5K Hold
200
– – ﹤0.01% 1155
2020
Q3 		$6K Buy
+200
New +$6.99K ﹤0.01% 1161

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quantbot Technologies's AKRO Position: Q4 2025 in Review

Quantbot Technologies sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 4,335 shares — an estimated $206K sold.

Quantbot Technologies first reported a position in AKRO in Q3 2020 and held it in 11 quarters. The position peaked at $1.03M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Quantbot Technologies reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quantbot Technologies sold 4,335 Akero Therapeutics shares in Q4 2025, an estimated $206K.
  • Quantbot Technologies first reported a position in Akero Therapeutics in Q3 2020 and held it in 11 quarters.
  • Quantbot Technologies's Akero Therapeutics position peaked at $1.03M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Quantbot Technologies's 13F filing for Q4 2025, filed 10 Feb 2026.